downloadGenomic Health® is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer.

The company’s flagship product, the Oncotype DX®, breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in ductal carcinoma in situ (DCIS). With half a million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalised medicine by making genomics a critical part of cancer diagnosis and treatment.